253 related articles for article (PubMed ID: 14760795)
21. Interleukin-10 gene polymorphisms are associated with the SLICC/ACR Damage Index in systemic lupus erythematosus.
Sung YK; Park BL; Shin HD; Kim LH; Kim SY; Bae SC
Rheumatology (Oxford); 2006 Apr; 45(4):400-4. PubMed ID: 16287924
[TBL] [Abstract][Full Text] [Related]
22. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease.
Lee TJ; Chun JK; Yeon SI; Shin JS; Kim DS
Scand J Rheumatol; 2007; 36(3):222-5. PubMed ID: 17657678
[TBL] [Abstract][Full Text] [Related]
23. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
24. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the results of the migration inhibitory factor production test with DNA and the severity of the disease in the systemic lupus erythematosus patients.
Rovenský J; Svejcar J; Pekárek J; Zitnan D; Hajzok O; Cebecauer L
Z Immunitatsforsch Exp Klin Immunol; 1975 Aug; 150(1):24-30. PubMed ID: 127462
[TBL] [Abstract][Full Text] [Related]
26. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity.
Martens HA; Zuurman MW; de Lange AH; Nolte IM; van der Steege G; Navis GJ; Kallenberg CG; Seelen MA; Bijl M
Ann Rheum Dis; 2009 May; 68(5):715-20. PubMed ID: 18504288
[TBL] [Abstract][Full Text] [Related]
27. Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan.
Rabbani MA; Habib HB; Islam M; Ahmad B; Shah SM; Tahir S; Merchant D; Ahmad A
Lupus; 2010 Nov; 19(13):1573-8. PubMed ID: 20705644
[TBL] [Abstract][Full Text] [Related]
28. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of chemokines and chemokine receptors with clinical features in newly diagnosed systemic lupus erythematosus].
Tao JH; Li XP; Li XM; Kan M; Zhai ZM; Wang W
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3051-4. PubMed ID: 17288835
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
31. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.
Ainiala H; Hietaharju A; Dastidar P; Loukkola J; Lehtimäki T; Peltola J; Korpela M; Heinonen T; Nikkari ST
Arthritis Rheum; 2004 Mar; 50(3):858-65. PubMed ID: 15022328
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis.
Ayoub S; Hickey MJ; Morand EF
Nat Clin Pract Rheumatol; 2008 Feb; 4(2):98-105. PubMed ID: 18235539
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between macrophage migration inhibitory factor and cardiac function in patients with congestive heart failure].
Liu Y; Yu XY; Lin QX; Yang M; Shan ZX; Zheng M
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1169-70. PubMed ID: 14625178
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase-9 promoter polymorphisms in Korean patients with systemic lupus erythematosus.
Lee YJ; Woo M; Nam JH; Baek J; Im CH; Lee EY; Lee EB; Park KS; Song YW
Hum Immunol; 2008 Jun; 69(6):374-9. PubMed ID: 18571010
[TBL] [Abstract][Full Text] [Related]
36. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
37. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris.
Namazi MR; Fallahzadeh MK; Shaghelani H; Kamali-Sarvestani E
Int J Dermatol; 2010 Feb; 49(2):146-8. PubMed ID: 19799642
[TBL] [Abstract][Full Text] [Related]
38. Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with the MIF-173G/C polymorphism.
Rigante D; Flex A; Federico G; Pola R; Candelli M; Manna R; Pugliese AL; Cerquaglia C; Compagnone A; Stabile A
Scand J Rheumatol; 2007; 36(4):307-10. PubMed ID: 17763209
[TBL] [Abstract][Full Text] [Related]
39. Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis.
Morin M; Bellehumeur C; Therriault MJ; Metz C; Maheux R; Akoum A
Fertil Steril; 2005 Apr; 83(4):865-72. PubMed ID: 15820792
[TBL] [Abstract][Full Text] [Related]
40. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
